Real-world palbociclib dose modifications and clinical outcomes in patients with HR+/HER2− metastatic breast cancer: A Flatiron Health database analysis

Purpose: To examine the associations of palbociclib dose modifications with clinical outcomes of patients with HR+/HER2− metastatic breast cancer (MBC) treated with first-line (1L) palbociclib + aromatase inhibitor (AI) in routine practice. Methods: Using the Flatiron Health Analytic Database, we co...

Full description

Saved in:
Bibliographic Details
Main Authors: Rachel M. Layman, Xianchen Liu, Benjamin Li, Lynn McRoy, Adam Brufsky
Format: Article
Language:English
Published: Elsevier 2025-06-01
Series:Breast
Subjects:
Online Access:http://www.sciencedirect.com/science/article/pii/S0960977625004655
Tags: Add Tag
No Tags, Be the first to tag this record!